Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease.
about
Identification of genes associated with dissociation of cognitive performance and neuropathological burden: Multistep analysis of genetic, epigenetic, and transcriptional dataExploring the nexus of Alzheimer's disease and related dementias with cancer and cancer therapies: A convening of the Alzheimer's Association & Alzheimer's Drug Discovery Foundation.Current advances in systems and integrative biologySystems genetics identifies Hp1bp3 as a novel modulator of cognitive aging.The TMEM106B locus and TDP-43 pathology in older persons without FTLDRecent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease.Plasma Exosomal miRNAs in Persons with and without Alzheimer Disease: Altered Expression and Prospects for Biomarkers.Evaluation of logistic regression models and effect of covariates for case-control study in RNA-Seq analysis.Higher brain BDNF gene expression is associated with slower cognitive decline in older adults.Progressive MS: from pathophysiology to drug discovery.Psychotropic Drug Development Strategies that Target Neuropsychiatric Etiologies in Alzheimer's and Parkinson's Diseases.The Anti-Amyloid-β and Neuroprotective Properties of a Novel Tricyclic Pyrone Molecule.A Dopamine Receptor genetic variant enhances perceptual speed in cognitive healthy subjectsRecent Advances in the Systems Biology of Aging.Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE ε4 haplotype status: a community-based cohort study
P2860
Q30000273-CD5143B7-88DF-4DF0-85DB-FA6CF60937E1Q30239964-58BCD733-F60D-4BD4-98AF-6C81A9770921Q34417712-C2A6EBDF-4233-463B-911C-3AD21EA21291Q34535421-3025078C-D8F9-42FE-AFE0-81933D34BA85Q35153681-E169967E-BE09-4BD7-9025-13BE3F3998ACQ35617556-7F9A9273-4048-4BCA-8326-FEDC3E8D8D4DQ35795155-B4445BBF-DEA0-4ECC-A6E6-D44C6C7B7A98Q36271926-DC86E5BB-88E9-4D41-8AD5-8B8D51D7B830Q36607667-E9B5F507-5117-40BD-822F-682727AD3233Q38585418-345A521A-A311-4C49-9EF2-BD896E7279CCQ38998475-54A6B81B-3A1C-4C45-BA50-B26A340A32BDQ42254678-A4BF370B-AE1E-4D1B-A358-BBE45D50BF28Q42711931-5A4ED357-FE25-450E-A18A-55BD6263E92FQ47819372-1ACE4D6E-234E-43BC-8B04-852A6511C290Q57165224-8B2A3E1E-848A-4D03-A884-254F7E382AAA
P2860
Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Building a pipeline to discove ...... ounds for Alzheimer's disease.
@ast
Building a pipeline to discove ...... ounds for Alzheimer's disease.
@en
type
label
Building a pipeline to discove ...... ounds for Alzheimer's disease.
@ast
Building a pipeline to discove ...... ounds for Alzheimer's disease.
@en
prefLabel
Building a pipeline to discove ...... ounds for Alzheimer's disease.
@ast
Building a pipeline to discove ...... ounds for Alzheimer's disease.
@en
P2860
P1476
Building a pipeline to discove ...... ounds for Alzheimer's disease.
@en
P2093
Philip L De Jager
P2860
P304
P356
10.1016/J.BCP.2014.01.037
P407
P577
2014-02-06T00:00:00Z